Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.
GLP-1 receptor agonists
Obesity
Once-weekly semaglutide
Type 2 diabetes mellitus
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
22
12
2021
accepted:
29
03
2022
pubmed:
17
4
2022
medline:
14
7
2022
entrez:
16
4
2022
Statut:
ppublish
Résumé
Registered trials and real-world evidence (RWE) studies provided evidence on the efficacy of once-weekly (OW) semaglutide on hyperglycaemia and cardiovascular risk factors as add-on or de-novo treatment in type 2 diabetes (T2D). In a retrospective analysis of electronic data files from 258 T2D patients, this RWE study aimed to explore the impact of OW semaglutide on biochemical and anthropometric outcomes after 6 and 12 months in patients receiving at least one prescription of OW semaglutide between September 2019 and May 2021. During the study period, 154 and 56 consecutive patients completed the 6 and 12 months of OW semaglutide treatment. HbA1c levels decreased by -1.02±0.1% after 6 months and -1.1±0.1% after 12 months of OW semaglutide (p<0.0001 for both). At these time-points, HbA1c values were <7% in 61% and 57% of cases. HbA1c reduction was greater in patients with higher baseline HbA1c levels and it occurred irrespective of gender, age, insulin therapy and complications. The residual number of cases with HbA1c ≥9% by the study end was low (5.3% vs 18.9% at baseline). Weight loss occurred in 73.5% and 78.1% of cases and, compared to baseline, it was ≥5% in 21.2- 25.4% and ≥10% in 6.8-18.2% after 6 and 12 months, respectively. Significant predictors of HbA1c reduction after 6 months of OW semaglutide treatment were baseline HbA1c (p<0.0001), bodyweight reduction (p<0.0001) and disease duration (p<0.001), while baseline HbA1c was the only predictor of HbA1c response after 12 months (p<0.0001). Reported adverse events were consistent with the known safety profile of semaglutide. Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.
Identifiants
pubmed: 35429298
doi: 10.1007/s40618-022-01799-2
pii: 10.1007/s40618-022-01799-2
pmc: PMC9270295
doi:
Substances chimiques
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
semaglutide
53AXN4NNHX
Glucagon-Like Peptides
62340-29-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1587-1598Informations de copyright
© 2022. The Author(s).
Références
Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409–1439. https://doi.org/10.1152/physrev.00034.2006
doi: 10.1152/physrev.00034.2006
pubmed: 17928588
Brandt SJ, Götz A, Tschöp MH, Müller TD (2018) Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides 100:190–201. https://doi.org/10.1016/j.peptides.2017.12.021
doi: 10.1016/j.peptides.2017.12.021
pubmed: 29412819
pmcid: 5805859
Nolen-Doerr E, Stockman MC, Rizo I (2019) Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity. Curr Obes Rep 8:284–291. https://doi.org/10.1007/s13679-019-00350-4
doi: 10.1007/s13679-019-00350-4
pubmed: 31124035
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee; LEADER Trial Investigators (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322. https://doi.org/10.1056/NEJMoa1603827
doi: 10.1056/NEJMoa1603827
pubmed: 27295427
pmcid: 4985288
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844. https://doi.org/10.1056/NEJMoa160714
doi: 10.1056/NEJMoa160714
pubmed: 27633186
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T, REWIND Investigators (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
doi: 10.1016/S0140-6736(19)31149-3
pubmed: 31189511
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC, PIONEER 6 Investigators (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381:841–851. https://doi.org/10.1056/NEJMoa1901118
doi: 10.1056/NEJMoa1901118
pubmed: 31185157
Iacobellis G, Baroni MG (2022) Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. J Endocrinol Invest 45:489–495. https://doi.org/10.1007/s40618-021-01687-1
doi: 10.1007/s40618-021-01687-1
pubmed: 34643917
Vitale M, Haxhi J, Cirrito T, Pugliese G (2020) Renal protection with glucagon-like peptide-1 receptor agonists. Curr Opin Pharmacol 54:91–101. https://doi.org/10.1016/j.coph.2020.08.018
doi: 10.1016/j.coph.2020.08.018
pubmed: 33027748
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305. https://doi.org/10.1056/NEJMoa041031 (Erratum. In: N Engl J Med (2008) 18:4)
doi: 10.1056/NEJMoa041031
pubmed: 15385656
Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776–785. https://doi.org/10.1016/S2213-8587(19)30249-9 (Erratum. In: Lancet Diabetes Endocrinol (2020) 8:e2)
doi: 10.1016/S2213-8587(19)30249-9
pubmed: 31422062
Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR, Lo KB, Tuttle K, Vaduganathan M, Ventura H, McCullough PA, American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Lifestyle and Cardiometabolic Health (2020) Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: A scientific statement from the American Heart Association. Circulation 142:e265–e286. https://doi.org/10.1161/CIR.0000000000000920 (Erratum in Circulation (2020) 142:e304)
doi: 10.1161/CIR.0000000000000920
pubmed: 32981345
Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D’Alessio DA, Davies MJ (2020) 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43:487–493. https://doi.org/10.2337/dci19-0066 (Erratum in Diabetes Care (2020) 43:1670)
doi: 10.2337/dci19-0066
pubmed: 31857443
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC, ESC Scientific Document Group (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41:255–323. https://doi.org/10.1093/eurheartj/ehz486 (Erratum in Eur Heart J (2020) 41:4317)
doi: 10.1093/eurheartj/ehz486
pubmed: 31497854
Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T (2015) Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 58:7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726
doi: 10.1021/acs.jmedchem.5b00726
pubmed: 26308095
European Medicines Agency (EMA) (2018) Ozempic – Semaglutide. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf . Accessed 24 June 2021
Tilinca MC, Tiuca RA, Niculas C, Varga A, Tilea I (2021) Future perspectives in diabesity treatment: semaglutide, a glucagon-like peptide 1 receptor agonist (Review). Exp Ther Med 22:1167. https://doi.org/10.3892/etm.2021.10601
doi: 10.3892/etm.2021.10601
pubmed: 34504612
pmcid: 8394024
Aroda VR, Capehorn MS, Chaykin L, Frias JP, Lausvig NL, Macura S, Lüdemann J, Madsbad S, Rosenstock J, Tabak O, Tadayon S, Bain SC (2020) Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: a patient-level, pooled analysis of the SUSTAIN 1–5 trials. Diabetes Obes Metab 22:303–314. https://doi.org/10.1111/dom.13896
doi: 10.1111/dom.13896
pubmed: 31608552
Tan X, Cao X, Zhou M, Zou P, Hu J (2017) Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opin Investig Drugs 26:1083–1089. https://doi.org/10.1080/13543784.2017.1360274
doi: 10.1080/13543784.2017.1360274
pubmed: 28741970
Marso SP, Holst AG, Vilsbøll T (2017) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 376:891–892. https://doi.org/10.1056/NEJMc1615712
doi: 10.1056/NEJMc1615712
pubmed: 28249135
de Lusignan S, Crawford L, Munro N (2015) Creating and using real-world evidence to answer questions about clinical effectiveness. J Innov Health Inform. 22:368–373. https://doi.org/10.14236/jhi.v22i3.177
doi: 10.14236/jhi.v22i3.177
pubmed: 26577427
Florkowski CM, Chew-Harris JS (2011) Methods of estimating GFR—different equations including CKD-EPI. Clin Biochem Rev 32:75–79
pubmed: 21611080
pmcid: 3100284
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
Visaria J, Uzoigwe C, Swift C, Dang-Tan T, Paprocki Y, Willey VJ (2021) Real-world effectiveness of once-weekly semaglutide from a US commercially insured and Medicare advantage population. Clin Ther 43:808–821. https://doi.org/10.1016/j.clinthera.2021.03.003
doi: 10.1016/j.clinthera.2021.03.003
pubmed: 33785221
Brown RE, Bech PG, Aronson R (2020) Semaglutide once weekly in people with type 2 diabetes: real-world analysis of the Canadian LMC diabetes registry (SPARE study). Diabetes Obes Metab 22:2013–2020. https://doi.org/10.1111/dom.14117
doi: 10.1111/dom.14117
pubmed: 32538541
pmcid: 7689820
Hansen KB, Svendstrup M, Lund A, Knop FK, Vilsbøll T, Vestergaard H (2021) Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: real-world data from a diabetes out-patient clinic. Diabet Med 38:e14655. https://doi.org/10.1111/dme.14655
doi: 10.1111/dme.14655
pubmed: 34291491
Crabtree TSJ, Bickerton A, Sennik DK, Rohilla A, Sivappriyan S, Barnes D, Cull ML, Gallen IW, Adamson K, Ryder RE (2021) The Association of British Clinical Diabetologists (ABCD) United Kingdom Nationwide Semaglutide Audit. American Diabetes Association® (ADA) 81st Scientific Sessions, Poster 686
Lingvay I, Kirk AR, Lophaven S, Wolden ML, Shubrook JH (2021) Outcomes in GLP-1 RA-experienced patients switching to once-weekly semaglutide in a real-world setting: The Retrospective, Observational EXPERT Study. Diabetes Ther 12:879–896. https://doi.org/10.1007/s13300-021-01010-4
doi: 10.1007/s13300-021-01010-4
pubmed: 33594582
pmcid: 7947062
Jain AB, Kanters S, Khurana R, Kissock J, Severin N, Stafford SG (2021) Real-world effectiveness analysis of switching from liraglutide or dulaglutide to semaglutide in patients with type 2 diabetes mellitus: the retrospective REALISE-DM Study. Diabetes Ther 12:527–536. https://doi.org/10.1007/s13300-020-00984-x
doi: 10.1007/s13300-020-00984-x
pubmed: 33367981
Hepprich M, Zillig D, Florian-Reynoso MA, Donath MY, Rudofsky G (2021) Switch-to-semaglutide study (STS-Study): a retrospective cohort study. Diabetes Ther 12:943–954. https://doi.org/10.1007/s13300-021-01016-y
doi: 10.1007/s13300-021-01016-y
pubmed: 33615400
pmcid: 7947039
Goncalves E, Bell DS (2020) Efficacy of semaglutide versus liraglutide in clinical practice. Diabetes Metab 46:515–517. https://doi.org/10.1016/j.diabet.2019.10.001
doi: 10.1016/j.diabet.2019.10.001
pubmed: 31606525
Williams DM, Ruslan AM, Khan R, Vijayasingam D, Iqbal F, Shaikh A, Lim J, Chudleigh R, Peter R, Udiawar M, Bain SC, Stephens JW, Min T (2021) Real-world clinical experience of semaglutide in secondary care diabetes: a retrospective observational study. Diabetes Ther 12:801–811. https://doi.org/10.1007/s13300-021-01015-z
doi: 10.1007/s13300-021-01015-z
pubmed: 33565043
pmcid: 7872110
Tofé S, Argüelles I, Mena E, Serra G, Codina M, Urgelés JR, García H, Pereg V (2021) An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs subcutaneous semaglutide in Spain. Endocrine and Metabolic Science 2:100082. https://doi.org/10.1016/j.endmts.2021.100082
doi: 10.1016/j.endmts.2021.100082
Holmes P, Bell HE, Bozkurt K, Catarig AM, Clark A, Machell A, Sathyapalan T (2021) Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE UK multicentre, prospective, observational study. Diabetes Ther 12:2891–2905. https://doi.org/10.1007/s13300-021-01141-8
doi: 10.1007/s13300-021-01141-8
pubmed: 34562237
pmcid: 8475854
Ferrer-García JC, Albalat Galera R, Arribas L, Tolosa Torrens M, Sánchez Lorente A, Portilla AJ, Artero A, Sánchez-Juan C (2020) Receptor agonist in type 2 diabetes: a study to evaluate real-world effectiveness. American Diabetes Association® (ADA) 80th Scientific Sessions, 69 (Suppl 1), Abstract 947-P
Tong J, Jain A, Stafford S (2020) Comparative analysis of A1c and weight reduction potential of subcutaneous GLP-1 receptor agonists in a real-world setting. CJD 44:S23–S24. https://doi.org/10.1016/j.jcjd.2020.08.061
doi: 10.1016/j.jcjd.2020.08.061
Garcia de Lucas MD, Pérez-Belmonte LM, Aviles B, Jimenez AI, Fernandez JM, Rivas Ruiz F (2021) Semaglutide Achieves Better Metabolic and Weight Control than Other GLP-1 RA in Real Life after 12 Months of Follow-up. American Diabetes Association® (ADA) 81st Scientific Sessions, Poster 676
Balcazar CM, Zambrano J, Garcia AF, Casanova ME (2021) Semaglutide once weekly in persons with type 2 diabetes: real-world analysis of the Colombian Diabetes Registry (COL-REAL 1 Study). Metab Clin Exp 116:154640. https://doi.org/10.1016/j.metabol.2020.154640
doi: 10.1016/j.metabol.2020.154640
Cárdenas-Salas JJ, Sierra R, Luca BL, Sanchez B, Modroño N, Casado C, Sanchez NM, Cruces E, Vazquez C (2021) Semaglutide in patients with type 2 diabetes: real-world data from Spain. American Diabetes Association® (ADA) 81st Scientific Sessions, Poster 690
Rudofsky G, Catarig AM, Favre L, Grau K, Häfliger S, Thomann R, Schultes B (2021) Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Res Clin Pract 178:108931. https://doi.org/10.1016/j.diabres.2021.108931
doi: 10.1016/j.diabres.2021.108931
pubmed: 34217773
Yale JF, Catarig AM, Grau K, Harris S, Klimek-Abercrombie A, Rabasa-Lhoret R, Reardon L, Woo V, Liutkus J (2021) Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study. Diabetes Obes Metab 23:2269–2278. https://doi.org/10.1111/dom.14468
doi: 10.1111/dom.14468
pubmed: 34142429
pmcid: 9291287
Uzoigwe C, Liang Y, Whitmire S, Paprocki Y (2021) Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting. Diabetes Ther 12:1475–1489. https://doi.org/10.1007/s13300-021-01053-7
doi: 10.1007/s13300-021-01053-7
pubmed: 33837922
pmcid: 8099966
Al Hayek AA, Al Dawish MA (2022) Evaluation of patient-reported satisfaction and clinical efficacy of once-weekly semaglutide in patients with type 2 diabetes: an ambispective study. Adv Ther. https://doi.org/10.1007/s12325-022-02053-0
doi: 10.1007/s12325-022-02053-0
pubmed: 35119622
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (2018) Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41:2669–2701. https://doi.org/10.2337/dci18-0033
doi: 10.2337/dci18-0033
pubmed: 30291106
pmcid: 6245208
American Diabetes Association (2022) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes. Diabetes Care 45:S125–S143. https://doi.org/10.2337/dc22-S009
doi: 10.2337/dc22-S009
Honigberg MC, Chang LS, McGuire DK, Plutzky J, Aroda VR, Vaduganathan M (2020) Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review. JAMA Cardiol 5:1182–1190. https://doi.org/10.1001/jamacardio.2020.1966
doi: 10.1001/jamacardio.2020.1966
pubmed: 32584928
pmcid: 7744318
Gardner H, Hamdy O (2020) Oral GLP1 analog: where does the tide go? Clin Med Insights Endocrinol Diabetes 13:1179551420984130. https://doi.org/10.1177/1179551420984130
doi: 10.1177/1179551420984130
pubmed: 33447122
pmcid: 7780176
Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR (2018) Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care 41:258–266. https://doi.org/10.2337/dc17-0417
doi: 10.2337/dc17-0417
pubmed: 29246950
Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A, SUSTAIN 7 Investigators (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6:275–286. https://doi.org/10.1016/S2213-8587(18)30024-X
doi: 10.1016/S2213-8587(18)30024-X
pubmed: 29397376
Wang W, Wen X, Duan W, Wang X, Chen Y, Dong J, Yang Z, Fang J, Zhou Z, Yao G, Fang Y, Huang Y (2020) DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus. J Endocrinol Invest 43:653–662. https://doi.org/10.1007/s40618-019-01153-z
doi: 10.1007/s40618-019-01153-z
pubmed: 31786794
Anderson SL, Beutel TR, Trujillo JM (2020) Oral semaglutide in type 2 diabetes. J Diabetes Complications 34:107520. https://doi.org/10.1016/j.jdiacomp.2019.107520
doi: 10.1016/j.jdiacomp.2019.107520
pubmed: 31952996
Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, Lingvay I, Thomsen M, Wadden TA, Wharton S, Wilding JPH, Rubino D (2020) Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP Trials 1 to 5. Obesity (Silver Spring) 28:1050–1061. https://doi.org/10.1002/oby.22794
doi: 10.1002/oby.22794
pmcid: 7318657
DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V (2020) Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials. J Clin Endocrinol Metab 105:72. https://doi.org/10.1210/clinem/dgz072
doi: 10.1210/clinem/dgz072
Zavattaro M, Caputo M, Samà MT, Mele C, Chasseur L, Marzullo P, Pagano L, Mauri MG, Ponziani MC, Aimaretti G, Prodam F (2015) One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine 50:620–626. https://doi.org/10.1007/s12020-014-0519-0
doi: 10.1007/s12020-014-0519-0
pubmed: 25572181
Mann JFE, Hansen T, Idorn T, Leiter LA, Marso SP, Rossing P, Seufert J, Tadayon S, Vilsbøll T (2020) Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes Endocrinol 28:880–893. https://doi.org/10.1016/S2213-8587(20)30313-2
doi: 10.1016/S2213-8587(20)30313-2
Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR (2005) Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 28:995–1000. https://doi.org/10.2337/diacare.28.5.995
doi: 10.2337/diacare.28.5.995
pubmed: 15855556
Rajamand Ekberg N, Bodholdt U, Catarig AM, Catrina SB, Grau K, Holmberg CN, Klanger B, Knudsen ST (2021) Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study. Prim Care Diabetes 15:871–878. https://doi.org/10.1016/j.pcd.2021.06.008
doi: 10.1016/j.pcd.2021.06.008
pubmed: 34183269
Pineda ED, Liao IC, Godley PJ, Michel JB, Rascati KL (2020) Cardiovascular outcomes among patients with type 2 diabetes newly initiated on sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and other antidiabetic medications. J Manag Care Spec Pharm 26:610–618. https://doi.org/10.18553/jmcp.2020.26.5.610
doi: 10.18553/jmcp.2020.26.5.610
pubmed: 32347181
Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, Rowe E, DeVries JH (2017) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol 5:355–366. https://doi.org/10.1016/S2213-8587(17)30085-2
doi: 10.1016/S2213-8587(17)30085-2
pubmed: 28344112
Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, Araki E, Chu PL, Wijayasinghe N, Norwood P (2018) Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab 103:2291–2301. https://doi.org/10.1210/jc.2018-00070
doi: 10.1210/jc.2018-00070
pubmed: 29688502
pmcid: 5991220
Hunt B, Malkin SJP, Moes RGJ, Huisman EL, Vandebrouck T, Wolffenbuttel BHR (2019) Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ Open Diabetes Res Care 7:e000705. https://doi.org/10.1136/bmjdrc-2019-0
doi: 10.1136/bmjdrc-2019-0
pubmed: 31641522
pmcid: 6777406